BRISTOL, TN--(Marketwire - February 18, 2010) - King Pharmaceuticals, Inc. (NYSE: KG) announced today that the Company plans to report financial results for the fourth quarter and year ended December 31, 2009, prior to the market open on Thursday, February 25, 2010. The Company also plans to provide a live conference call which may include discussion of the Company’s marketed products, pipeline, financial results and expectations, and other matters relating to its business beginning at 11:00 a.m. EST that same day. This call will be open to all interested parties and may be accessed by using the following information:
Conference Call Access Domestic Dial In: (888) 674-0224 International Dial-In: (201) 604-0502
Interested parties may also listen to the web cast by clicking on the following link to register and then joining the live event with the same URL:
http://www.kingpharm.com/Investors/Webcasts.cfm
If you are unable to participate during the live event, the replay number is 888-632-8973, or 201-499-0429 if you are calling from outside the USA. The replay code is 77910286, followed by the # sign. The web cast of our call on February 25th will be archived on King’s web site, accessible through the link above, for not less than 14 days.
King, headquartered in Bristol, Tennessee, is a vertically integrated branded pharmaceutical company. King, an S&P 500 Index company, seeks to capitalize on opportunities in the pharmaceutical industry through the development, including through in-licensing arrangements and acquisitions, of novel branded prescription pharmaceutical products and technologies that complement the Company’s focus in specialty-driven markets, particularly neuroscience and hospital. King’s wholly owned subsidiary, Alpharma Inc., is also a leader in the development, registration, manufacture and marketing of pharmaceutical products for food producing animals.
This release contains forward-looking statements which reflect management’s current views of future events and operations, including, but not limited to, statements pertaining to the anticipated date for release of the Company’s financial results for the fourth quarter and year ended December 31, 2009. These forward-looking statements involve certain significant risks and uncertainties, and actual results may differ materially from the forward-looking statements. Some important factors which may cause results to differ include King’s ability to release the Company’s financial results as currently planned on February 25, 2010. Other important factors that may cause actual results to differ materially from the forward-looking statements are discussed in the “Risk Factors” section and other sections of King’s Form 10-K for the year ended December 31, 2008 and Form 10-Q for the quarter ended September 30, 2009 which are on file with the U.S. Securities and Exchange Commission. King does not undertake to publicly update or revise any of its forward-looking statements even if experience or future changes show that the indicated results or events will not be realized.
EXECUTIVE OFFICES KING PHARMACEUTICALS, INC. 501 FIFTH STREET, BRISTOL, TENNESSEE 37620
Contact:
Jack Howarth
Vice President, Investor Relations
908-429-8350
